



Drake, M. J., Lewis, A. L., Young, G., Abrams, P. H., Blair, P. S., Chapple, C., Glazener, C., Horwood, J. P., McGrath, J., Noble, S. M., Taylor, G., & Lane, J. A. (2020). Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. *European Urology*, 78(5), 701-710.
<https://doi.org/10.1016/j.eururo.2020.06.004>

Peer reviewed version

Link to published version (if available):
[10.1016/j.eururo.2020.06.004](https://doi.org/10.1016/j.eururo.2020.06.004)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://doi.org/10.1016/j.eururo.2020.06.004> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Contributors

M Drake, J A Lane, P Abrams, P Blair, C Chapple, C Glazener, J Horwood, J McGrath, S Noble, G Taylor, A Lewis and G Young contributed to the design, conduct and management of the study. M Drake was the study Chief Investigator. G Young, P Blair, A Lewis and M Drake contributed to writing the statistical analysis plan. G Young conducted the statistical analysis, with oversight from the lead statistician, P Blair. M Drake, A Lewis and G Young drafted the manuscript, with review and contributions from all authors. All authors approved the final manuscript for publication.

Declaration of interests

Outside this work, Paul Abrams reports grants and personal fees for being a consultant and speaker for Astellas Pharma Inc. (Tokyo, Japan), and personal fees for being a consultant for Ipsen (Paris, France) and a speaker for Pfizer Inc. (New York City, NY, USA) and Sun Pharmaceutical Industries Ltd (Mumbai, India). He also reports personal fees from Pierre Fabre S.A. (Paris, France) and Coloplast Ltd (Peterborough, UK). Christopher Chapple reports being an author for Allergan plc (Dublin, Ireland) and Astellas Pharma; being an investigator for scientific studies/trials with Astellas Pharma and Ipsen; being a patent holder with Symimetics; receiving personal fees as a consultant/ advisor for Astellas Pharma, Bayer Schering Pharma GmbH (Berlin, Germany), Ferring Pharmaceuticals (Saint-Prex, Switzerland), Galvani Bioelectronics (GlaxoSmithKline; Stevenage, UK), Pierre Fabre, Symimetics, TARIS Biomedical Inc. (Lexington, MA, USA), and Urovant Sciences (Irvine, CA, USA); and receiving personal fees as a meeting participant/speaker for Astellas Pharma and Pfizer. Marcus J Drake reports being on associated advisory boards and has received grants, personal fees and non-financial support from Allergan, Astellas Pharma and Ferring Pharmaceuticals. He has also received personal fees from Pfizer. J Athene Lane was a member of the Clinical Trials Unit funded by the National Institute for Health Research during the conduct of this trial. Paul Abrams, Peter Blair, Chris Chapple, Cathryn Glazener, Jeremy Horwood, Athene Lane, John McGrath, Sian Noble and Gordon Taylor were co-applicants of the UPSTREAM trial, thus received grant funding. Amanda Lewis and Grace Young were funded by the UPSTREAM trial. Grace Young is also in receipt of NIHR funding as part of a pre-doctoral fellowship.

All other authors: Nothing to declare.